Nitritex Ltd is a leading manufacturer of an extensive range of high quality cleanroom consumables, marketed under the BioClean™ brand. Products include gloves, goggles, masks and garments designed for critical environments where product and process protection is paramount
BioClean BarrierPlus™ Sterile Gauntlets (S-BBNG) are designed for use in highly controlled environments setting the standard for cleanliness and quality assurance.
Processed in an ISO Class 4 Cleanroom, BioClean BarrierPlus gauntlets have incredibly low levels of particulates and are packed in cleanroom compatible EasyTear™ packaging. Manufactured from white-coloured accelerator-free nitrile (a stretchy, synthetic rubber), they are resistant to a wide range of chemicals, including a selection of commonly-used chemotherapy drugs. Nitrile also exhibits excellent ESD (Electrostatic Dissipative) properties.
Each BioClean BarrierPlus gauntlet is visually inspected for holes on five separate occasions throughout the manufacturing process, along with water and air pressure testing, to guarantee delivery of a gauntlet 100% free from holes.
BioClean BarrierPlus™ Sterile Gauntlets are available in lengths of up to 840mm (33”) and three port sizes from 150mm to 300mm (6.0” to 12”).
Also available from the BioClean BarrierPlus range is a sterile mitten (S-BBNM) for use when interventions are rare and access speed is critical, and a sleeve (S-BBNS0) available in lengths of up to 660mm (26”), and suitable for port sizes from 150mm (6.0”) to 300mm (12”). With a cuff diameter of 90mm (3.5”) the sleeves will fit the majority of available cuff ring systems.
Contact Details:
Nitritex Ltd
Minton Enterprise Park, Oaks Drive
Newmarket, Suffolk, CB8 7YY
www.bioclean.com, info@bioclean.com
Tel: +44 1638 663338
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.